Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 126

1.

High prevalence and incidence of human papillomavirus in a cohort of healthy young African female subjects.

Watson-Jones D, Baisley K, Brown J, Kavishe B, Andreasen A, Changalucha J, Mayaud P, Kapiga S, Gumodoka B, Hayes RJ, de Sanjosé S.

Sex Transm Infect. 2013 Aug;89(5):358-65. doi: 10.1136/sextrans-2012-050685. Epub 2013 Mar 13.

PMID:
23486859
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial.

Kreimer AR, González P, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jiménez S, Schiller JT, Lowy DR, van Doorn LJ, Struijk L, Quint W, Chen S, Wacholder S, Hildesheim A, Herrero R; CVT Vaccine Group.

Lancet Oncol. 2011 Sep;12(9):862-70. doi: 10.1016/S1470-2045(11)70213-3. Epub 2011 Aug 22. Erratum in: Lancet Oncol. 2011 Nov;12(12):1096.

PMID:
21865087
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Frequency and risk factors for prevalent, incident, and persistent genital carcinogenic human papillomavirus infection in sexually active women: community based cohort study.

Oakeshott P, Aghaizu A, Reid F, Howell-Jones R, Hay PE, Sadiq ST, Lacey CJ, Beddows S, Soldan K.

BMJ. 2012 Jun 22;344:e4168. doi: 10.1136/bmj.e4168.

PMID:
22730542
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening.

Sigurdsson K, Sigvaldason H, Gudmundsdottir T, Sigurdsson R, Briem H.

Acta Obstet Gynecol Scand. 2009;88(1):27-35. doi: 10.1080/00016340802566770.

PMID:
19031282
[PubMed - indexed for MEDLINE]
5.

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.

Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.

J Natl Cancer Inst. 2010 Mar 3;102(5):325-39. doi: 10.1093/jnci/djp534. Epub 2010 Feb 5.

PMID:
20139221
[PubMed - indexed for MEDLINE]
Free Article
6.

Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.

Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, Langley JM, Bettinger JA, Singer J, Money D, Miller D, Naus M, Marra F, Young E.

JAMA. 2013 May 1;309(17):1793-802. doi: 10.1001/jama.2013.1625.

PMID:
23632723
[PubMed - indexed for MEDLINE]
7.

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.

Muñoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, Bautista O, Bryan J, Taddeo FJ, Esser MT, Vuocolo S, Haupt RM, Barr E, Saah A.

Lancet. 2009 Jun 6;373(9679):1949-57. doi: 10.1016/S0140-6736(09)60691-7. Epub 2009 Jun 1.

PMID:
19493565
[PubMed - indexed for MEDLINE]
8.

HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.

Castellsagué X, Schneider A, Kaufmann AM, Bosch FX.

Gynecol Oncol. 2009 Dec;115(3 Suppl):S15-23. doi: 10.1016/j.ygyno.2009.09.021. Epub 2009 Oct 12.

PMID:
19819540
[PubMed - indexed for MEDLINE]
9.

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.

Bhatla N, Suri V, Basu P, Shastri S, Datta SK, Bi D, Descamps DJ, Bock HL; Indian HPV Vaccine Study Group.

J Obstet Gynaecol Res. 2010 Feb;36(1):123-32. doi: 10.1111/j.1447-0756.2009.01167.x. Erratum in: J Obstet Gynaecol Res. 2010 Apr;36(2):466.

PMID:
20178538
[PubMed - indexed for MEDLINE]
10.

Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives.

Insinga RP, Dasbach EJ, Elbasha EH, Liaw KL, Barr E.

Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):709-15.

PMID:
17416761
[PubMed - indexed for MEDLINE]
Free Article
11.

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.

GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, Aoki F, Ramjattan B, Shier RM, Somani R, Barbier S, Blatter MM, Chambers C, Ferris D, Gall SA, Guerra FA, Harper DM, Hedrick JA, Henry DC, Korn AP, Kroll R, Moscicki AB, Rosenfeld WD, Sullivan BJ, Thoming CS, Tyring SK, Wheeler CM, Dubin G, Schuind A, Zahaf T, Greenacre M, Sgriobhadair A.

Lancet. 2009 Dec 12;374(9706):1975-85. doi: 10.1016/S0140-6736(09)61567-1. Epub .

PMID:
19962185
[PubMed - indexed for MEDLINE]
12.

Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.

Denny L, Hendricks B, Gordon C, Thomas F, Hezareh M, Dobbelaere K, Durand C, Hervé C, Descamps D.

Vaccine. 2013 Nov 19;31(48):5745-53. doi: 10.1016/j.vaccine.2013.09.032. Epub 2013 Oct 1.

PMID:
24091311
[PubMed - indexed for MEDLINE]
Free Article
13.

A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination.

Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Pearse A, Montoya GD, Robertson M, Shearman CA, Castle PE; New Mexico HPV Pap Registry Steering Committee.

Int J Cancer. 2013 Jan 1;132(1):198-207. doi: 10.1002/ijc.27608. Epub 2012 Jun 20.

PMID:
22532127
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7.

Konno R, Dobbelaere KO, Godeaux OO, Tamura S, Yoshikawa H.

Int J Gynecol Cancer. 2009 Jul;19(5):905-11. doi: 10.1111/IGC.0b013e3181a23c0e.

PMID:
19574783
[PubMed - indexed for MEDLINE]
15.

Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women.

Sow PS, Watson-Jones D, Kiviat N, Changalucha J, Mbaye KD, Brown J, Bousso K, Kavishe B, Andreasen A, Toure M, Kapiga S, Mayaud P, Hayes R, Lebacq M, Herazeh M, Thomas F, Descamps D.

J Infect Dis. 2013 Jun 1;207(11):1753-63. doi: 10.1093/infdis/jis619. Epub 2012 Dec 13.

PMID:
23242542
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Prevalence, incidence and persistence of genital HPV infections in a large cohort of sexually active young women in the Netherlands.

Mollers M, Boot Hein J, Vriend Henrike J, King Audrey J, van den Broek Ingrid VF, van Bergen Jan EA, Brink Antoinette AT, Wolffs Petra FG, Hoebe Christian JP, Meijer Chris JL, van der Sande Marianne AB, de Melker Hester E.

Vaccine. 2013 Jan 2;31(2):394-401. doi: 10.1016/j.vaccine.2012.10.087. Epub 2012 Nov 10.

PMID:
23146675
[PubMed - indexed for MEDLINE]
17.

Spectrum of genital human papillomavirus infection in a female adolescent population.

Jamison JH, Kaplan DW, Hamman R, Eagar R, Beach R, Douglas JM Jr.

Sex Transm Dis. 1995 Jul-Aug;22(4):236-43.

PMID:
7482107
[PubMed - indexed for MEDLINE]
18.

Safety and immunogenicity profile of human papillomavirus-16/18 AS04 adjuvant cervical cancer vaccine: a randomized controlled trial in healthy adolescent girls of Bangladesh.

Khatun S, Akram Hussain SM, Chowdhury S, Ferdous J, Hossain F, Begum SR, Jahan M, Tabassum S, Khatun S, Karim AB.

Jpn J Clin Oncol. 2012 Jan;42(1):36-41. doi: 10.1093/jjco/hyr173.

PMID:
22194637
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policies.

Ribassin-Majed L, Lounes R, Clémençon S.

PLoS One. 2012;7(3):e32251. doi: 10.1371/journal.pone.0032251. Epub 2012 Mar 12.

PMID:
22427828
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up.

Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Krogh Gv, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E.

Br J Cancer. 2006 Dec 4;95(11):1459-66. Epub 2006 Nov 21.

PMID:
17117182
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk